Loading
Prostate cancer starts out fed by testosterone (hormone-sensitive) and shrinks when it is removed. When it learns to grow despite castrate testosterone levels it is called castration-resistant, a later and more dangerous stage with its own treatments.
Metastatic hormone-sensitive disease (mHSPC) is treated with androgen deprivation plus an ARPI (abiraterone, enzalutamide, apalutamide, darolutamide) and sometimes docetaxel (STAMPEDE, LATITUDE, ARASENS), which delays castration resistance by years. Castration-resistant disease (CRPC), defined by PSA or radiographic progression with testosterone <50 ng/dL, arises through androgen receptor amplification, mutations, splice variants (AR-V7) and intratumoural androgen synthesis; it is treated with ARPI switch, docetaxel and cabazitaxel, PARP inhibitors for HRR mutations, 177Lu-PSMA-617 (VISION, PSMAfore) and radium-223. Non-metastatic CRPC (rising PSA, clear scans) has its own approvals. Radiographic PFS (rPFS) is the usual endpoint.
In plain words · The hormone switch that drives prostate cancer, attacked by castration and by pills that block the receptor.
Showing the target this term concerns: Androgen receptor.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares TROPIC, PSMAfore, Androgen receptor pathway inhibitor (ARPI), VISION.
Shares LATITUDE, Androgen receptor pathway inhibitor (ARPI), Darolutamide, VISION.
Shares TAX 327, Androgen receptor pathway inhibitor (ARPI), What follows what in castration-resistant prostate cancer, Abiraterone acetate.
Shares Androgen receptor pathway inhibitor (ARPI), VISION, What follows what in castration-resistant prostate cancer, Enzalutamide.
Shares KEYNOTE-991, Androgen receptor pathway inhibitor (ARPI), Enzalutamide, Castration-resistant prostate cancer (CRPC).
Shares Disease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk, GETUG-AFU 15, STAMPEDE's arms, and what each one answered, LATITUDE.
Shares CYP17A1 (17-alpha-hydroxylase/17,20-lyase), Androgen receptor pathway inhibitor (ARPI), Enzalutamide, Castration-resistant prostate cancer (CRPC).
Shares Androgen receptor pathway inhibitor (ARPI), What follows what in castration-resistant prostate cancer, Abiraterone acetate, Castration-resistant prostate cancer (CRPC).